Comments from Genomma's CEO, Marco Sparvieri
"2025 was a challenging year, with like-for-like sales declining -4.3% due to a weak summer beverage season in Mexico, a softer overall consumption environment in the country, and execution gaps. Q4 like-for-like sales decreased -12.9% due to the Company's decision to significantly reduced Mexico Q4 sell-in to normalize elevated retailer inventories following two weak OTC and beverage seasons. Importantly, Q4 Mexico sell-out declined a moderate -2.2%, confirming that underlying consumer demand remains resilient. Despite topline pressure, Genomma Lab delivered a resilient year-end 23.4% EBITDA margin and maintained a healthy 107-day cash-conversion cycle, underscoring the strength of our business fundamentals, disciplined execution and cost containment across the organization. We responded decisively by unlocking MXN 1.1 billion in productivity savings to reinvest in our growth initiatives: product innovation, distribution expansion, enhanced in-store execution and stronger communication. While early 2026 will reflect higher OPEX and softer sales, we expect growth initiatives to gain traction in the second half of the year, supporting a recovery in operational leverage. 2025's downturn was cyclical, not structural, and our fundamentals remain solid. As we rebuild momentum for our next phase of sustained growth, Genomma Lab is well-positioned to emerge stronger from this cycle."
Q4 2025 and Full Year Financial Summary
The following table provides a summary of the Company's Income Statement, in millions of Mexican pesos.
Q4 2025
% sales
Q4 2024
% sales
var %
2025
% sales
2024
% sales
var %
Like-for-like Sales(1)
-12.9 %
-4.3 %
Net Sales
4,017.0
100 %
4,665.6
100 %
-13.9 %
17,541.2
100 %
18,606.9
100 %
-5.7 %
Gross Profit
2,449.2
61.0 %
2,941.7
